Patents by Inventor Satonori HIGUCHI

Satonori HIGUCHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11319296
    Abstract: An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I): (wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: May 3, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki Asada, Keisuke Hanada, Satonori Higuchi, Atsushi Naganawa, Yasuhiro Takeda
  • Publication number: 20220048881
    Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation is disclosed. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
    Type: Application
    Filed: October 29, 2021
    Publication date: February 17, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki ASADA, Kousuke Tani, Masaya Hirobe, Satonori Higuchi, Kazuhiro Fuchibe, Ryo Oikawa, Tohru Kotani, Hirotsugu Takano
  • Publication number: 20220033371
    Abstract: An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I): (wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.
    Type: Application
    Filed: September 19, 2019
    Publication date: February 3, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki ASADA, Keisuke HANADA, Satonori HIGUCHI, Atsushi NAGANAWA, Yasuhiro TAKEDA
  • Patent number: 11192876
    Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation is disclosed. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: December 7, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki Asada, Kousuke Tani, Masaya Hirobe, Satonori Higuchi, Kazuhiro Fuchibe, Ryo Oikawa, Tohru Kotani, Hirotsugu Takano
  • Publication number: 20210163466
    Abstract: A compound represented by general formula (I): (wherein in the formula, all the symbols have the same meanings as those described in the specification), or a pharmaceutically acceptable salt thereof is useful as a medicament's active ingredient having an EP4 receptor antagonistic activity, in preventing and/or treating disease caused by activation of an EP4 receptor.
    Type: Application
    Filed: May 21, 2018
    Publication date: June 3, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki ASADA, Kousuke TANI, Satonori HIGUCHI
  • Publication number: 20200102284
    Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation is disclosed. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
    Type: Application
    Filed: December 2, 2019
    Publication date: April 2, 2020
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki ASADA, Kousuke TANI, Masaya HIROBE, Satonori HIGUCHI, Kazuhiro FUCHIBE, Ryo OIKAWA, Tohru KOTANI, Hirotsugu TAKANO
  • Patent number: 10538502
    Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: January 21, 2020
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki Asada, Kousuke Tani, Masaya Hirobe, Satonori Higuchi, Kazuhiro Fuchibe, Ryo Oikawa, Tohru Kotani, Hirotsugu Takano
  • Publication number: 20180319764
    Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
    Type: Application
    Filed: July 18, 2018
    Publication date: November 8, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki ASADA, Kousuke TANI, Masaya HIROBE, Satonori HIGUCHI, Kazuhiro FUCHIBE, Ryo OIKAWA, Tohru KOTANI, Hirotsugu TAKANO
  • Patent number: 10077247
    Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: September 18, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki Asada, Kousuke Tani, Masaya Hirobe, Satonori Higuchi, Kazuhiro Fuchibe, Ryo Oikawa, Tohru Kotani, Hirotsugu Takano
  • Publication number: 20180002308
    Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
    Type: Application
    Filed: January 8, 2016
    Publication date: January 4, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki ASADA, Kousuke TANI, Masaya HIROBE, Satonori HIGUCHI, Kazuhiro FUCHIBE, Ryo OIKAWA, Tohru KOTANI, Hirotsugu TAKANO